Serum, Plasma, COVID-19
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box)
Calculation of Index of Positivity
Limit of Detection
Limit of Analytical sensitivity is 1:8 (binary dilution)
CV = 3.67 %
CV = 9.75 %
European Union: for in vitro diagnostic use
Rest of the world: for research use only!
The total assay time is less than 2 hours. For the detection of IgA antibodies against nucleocapsid protein (NP) of SARS-CoV-2 virus in human blood.
Diagnostic specificity: 97.7%
Diagnostic sensitivity: 97.4%
Assay format is 96 wells.
Components of the kit are provided ready to use or concentrated.
The kit contains Positive Control, Negative Control and Cut-off control material to calculate the index of positivity.
Since December 2019, outbreak of SARS-CoV-2 (COVID-19) infection has become a major epidemic threat in China and brought back the attention of pathogenic coronavirus to the spotlight. Nucleocapsid protein (NP) is the most abundant protein on the helical nucleocapsid of coronaviruses, which envelopes the entire genomic RNA. NP also interacts with other viron structural proteins to play important roles during host cell entry and virus particle assembly and release. Anti-NP antibodies have been shown to be the earliest and the most predominant antibodies detectable in patient’s blood samples after coronavirus infection. EIA COVID 19 NP IgA kit is a highly sensitive and specific ELISA kit for the precision detection and calculation of index positivity of anti-NP IgA class antibodies in human blood.